ArticleInternational journal of clinical and experimental medicine2014
Estrogen increases secretion of stromal cell derived factor-1 in human breast cancer cells.
Article in International journal of clinical and experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Hematogenous Dissemination of Mesenchymal Stem Cells from Endometriosis.Stem cells (Dayton, Ohio) · 2018Article
- Balance between Estrogens and Proinflammatory Cytokines Regulates Chemokine Production Involved in Thymic Germinal Center Formation.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveStromal cell derived factor-1 (SDF-1) is closely related to the biological characteristics of breast cancer. The aim of this article is to investigate if estrogen affects the biological characteristics of breast cancer via affecting secretion of SDF-1.
methodsThe breast cancer cell lines MCF-7 and MDA-MB-231 used in this study were divided into control group, estrogen group and estrogen plus estrogen receptor (ER) antagonist group. These groups were treated with different concentrations of 17-β estradiol or the same concentration of 17-β estradiol for different times, respectively. Enzyme-linked immunosorbent assay and semi-quantitative reverse transcriptase polymerase chain reaction were performed.
resultsSecretion of SDF-1 was detected in the cell basal medium of MCF-7. When adding a high physiological concentrations of 17-β estradiol (10(-7) mol/L), the levels of SDF-1 secretion achieved a peak at 2 h and it was 6 times of control group (1823.16 ± 325.18 pg/ml comparing to 308.23 ± 9.23 pg/ml, P < 0.01). However, this effect could be eliminated by the pure estrogen antagonist ICI182 or ICI780. The SDF-1 mRNA levels were consistent with the determined SDF-1 protein levels. At the time point of 2 h, for the 10(-7) mol/L group, the SDF-1 mRNA expression levels were higher than the antagonist group, with statistically significant differences (P < 0.05).
conclusionsIt was found that secretion of SDF-1 can be increased by the physiological concentrations of estrogen mainly through regulation of estrogen receptor.
Indexed as
Identifiers
25664066PMC4307513W2339509429What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.